ResMed Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.44 (market cap $296.92M). The key difference: ResMed Inc. is far larger — about 107.4× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and ResMed Inc. pays a 1.16% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| RMD | YMAG | |
|---|---|---|
Market Cap | $31.89B | $296.92M |
Volume | 618,314 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $277.88 | $15.68 |
52-Week Low | $182.82 | $10.76 |
Typical Hold Time | 51 Days | 62 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
YMAG trades at $11.44, down 0.44% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. Technical indicators show neutral oscillators but bearish momentum signals, with all support and resistance levels clustered around $11.
The outlook remains cautious due to the bearish technical setup and potential NAV volatility from underlying option strategies. Income-focused investors may find the distribution yield attractive, but price stability concerns persist given the concentrated support level and negative momentum indicators.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →